Veracyte Inc logo

VCYT - Veracyte Inc Share Price

$58.38 5.0  9.3%

Last Trade - 4:06pm

Sector
Healthcare
Size
Mid Cap
Market Cap £2.27bn
Enterprise Value £2.02bn
Revenue £82.7m
Position in Universe 1704th / 6566
Bullish
Bearish
Unlock VCYT Revenue
Momentum
Relative Strength (%)
1m +9.24%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -16.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
38.2 49.5 65.1 72.0 92.0 120.4 114.9 152.3 +25.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Veracyte Inc revenues decreased 8% to $82.9M. Net lossincreased from $5.1M to $26.9M. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsSelling and marketing increase of 20% to $23.2M (expense),Intangible asset amortization increase from $800K to $3.8M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VCYT Revenue Unlock VCYT Revenue

Net Income

VCYT Net Income Unlock VCYT Revenue

Normalised EPS

VCYT Normalised EPS Unlock VCYT Revenue

PE Ratio Range

VCYT PE Ratio Range Unlock VCYT Revenue

Dividend Yield Range

VCYT Dividend Yield Range Unlock VCYT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VCYT EPS Forecasts Unlock VCYT Revenue
Profile Summary

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated August 15, 2006
Public Since October 30, 2013
No. of Shareholders: n/a
No. of Employees: 354
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 57,897,321
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VCYT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VCYT
Upcoming Events for VCYT
Thursday 25th February, 2021 Estimate
Q4 2020 Veracyte Inc Earnings Release
Tuesday 4th May, 2021 Estimate
Q1 2021 Veracyte Inc Earnings Release
Frequently Asked Questions for Veracyte Inc
What is the Veracyte Inc share price?

As of 4:06pm, shares in Veracyte Inc are trading at $58.38, giving the company a market capitalisation of £2.27bn. This share price information is delayed by 15 minutes.

How has the Veracyte Inc share price performed this year?

Shares in Veracyte Inc are currently trading at $58.38 and the price has moved by 77.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Veracyte Inc price has moved by 56.08% over the past year.

What are the analyst and broker recommendations for Veracyte Inc?

Of the analysts with advisory recommendations for Veracyte Inc, there are there are currently 3 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Veracyte Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Veracyte Inc next release its financial results?

Veracyte Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Veracyte Inc dividend yield?

Veracyte Inc does not currently pay a dividend.

Does Veracyte Inc pay a dividend?

Veracyte Inc does not currently pay a dividend.

When does Veracyte Inc next pay dividends?

Veracyte Inc does not currently pay a dividend.

How do I buy Veracyte Inc shares?

To buy shares in Veracyte Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Veracyte Inc?

Shares in Veracyte Inc are currently trading at $58.38, giving the company a market capitalisation of £2.27bn.

Where are Veracyte Inc shares listed? Where are Veracyte Inc shares listed?

Here are the trading details for Veracyte Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: VCYT
What kind of share is Veracyte Inc?

Based on an overall assessment of its quality, value and momentum, Veracyte Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Veracyte Inc share price forecast 2021?

Shares in Veracyte Inc are currently priced at $58.38. At that level they are trading at 13.48% premium to the analyst consensus target price of 0.00.

Analysts covering Veracyte Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.626 for the next financial year.

How can I tell whether the Veracyte Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veracyte Inc. Over the past six months, the relative strength of its shares against the market has been 47.19%. At the current price of $58.38, shares in Veracyte Inc are trading at 50.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Veracyte Inc PE Ratio?

We were not able to find PE ratio data for Veracyte Inc.

Who are the key directors of Veracyte Inc?

Veracyte Inc's management team is headed by:

Bonnie Anderson - CHM
Giulia Kennedy - CSO
Frederick Cohen - IND
Karin Eastham - IND
John Bishop - LED
Robert Epstein - IND
Keith Kennedy - CFO
John Hanna - GMG
Jens Holstein - DRC
James Erlinger - EVP
Morten Frost - GMG
Who are the major shareholders of Veracyte Inc?

Here are the top five shareholders of Veracyte Inc based on the size of their shareholding:

ARK Investment Management LLC Investment Advisor
Percentage owned: 12.12% (7.02m shares)
William Blair Investment Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 9.81% (5.68m shares)
ARK Innovation ETF Mutual Fund
Percentage owned: 8.62% (4.99m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.25% (4.20m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 7.24% (4.19m shares)
Similar to VCYT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.